You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Advancing a Glioma Immunotherapy

    SBC: IN CYTU, INC.            Topic: 102

    DESCRIPTION provided by applicant A Phase II SBIR program of preclinical development is proposed for the development of an active specific immunotherapeutic called Cellariumandquot for treatment of glial cell based cancers Successful completion of this project will confirm therapeutic effect and pre clinical safety of the vaccine in preparation for first in human studies Upon demonstration of ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Phosphodiesterase-4B (PDE4B) Inhibitors for Alzheimer's Disease

    SBC: Tetra Discovery Partners, Inc.            Topic: 101

    Under the parent grantTetra Discovery Partners is developing phosphodiesteraseBPDE Ballosteric inhibitors as a treatment for major depressive disorderUniquelythe Tetra drug will address inflammation as a contributor to depressionThis is a new mechanism of action for an antidepressant drug which should prove complimentary to current therapeuticsThe company estimates thatof patients with depression ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Development of nucleic acid delivery platform based on polymeric CXCR4 antagonists

    SBC: Bohemica Pharmaceuticals, LLC            Topic: 100

    DESCRIPTION provided by applicant Therapeutics based on nucleic acids NA promise to revolutionize treatment of multiple diseases but their widespread use is currently limited by the lack of efficient delivery methods We have recently developed a new NA delivery platform based on polymeric CXCR inhibitors PCX suitable as dual function systems for simultaneous NA delivery and inhibition of ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Mutation Enriched Targeted Re Sequencing

    SBC: TRANSGENOMIC, INC.            Topic: 103

    DESCRIPTION provided by applicant Low level tumor associated somatic DNA mutations can have profound implications for development of metastasis prognosis choice of treatment follow up or early cancer detection Unless they are effectively detected these low level mutations can misinform patient management decisions or become missed opportunities for personalized medicine Widely used tech ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a Non adjuvanted VLP Vaccine against Stealth H N Influenza

    SBC: EPIVAX, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The avian origin H N influenza virus that emerged in humans in China in presents a unique challenge to vaccine development because it is poorly immunogenic Neutralizing antibodies are not detected in acute phase infection Anti H antibody responses are significantly delayed and exhibit low avidity in comparison with antibodies generated following seas ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Geostatistical software for spatial and multi-dimensional joinpoint regression analysis of time series of health outcomes

    SBC: BIO-ANALYTICS, INC.            Topic: 102

    DESCRIPTION provided by applicant Analyzing temporal trends in cancer incidence and mortality rates can provide a more comprehensive picture of the burden of the disease and generate new insights about the impact of various interventions Join point regression developed by NCI Surveillance Research Program is increasingly used to identify the timing and extent of changes in time series of heal ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a Novel Therapeutic for Diabetic Retinopathy

    SBC: Zietchick Research Institute, LLC            Topic: W

    DESCRIPTION provided by applicant Diabetes mellitus affects andgt million individuals worldwide and its incidence is increasing at alarming rates Diabetic retinopathy DR the most common complication of diabetes is the leading cause of new blindness in working aged persons in the United States Unfortunately existing therapies are limited to advanced forms of DR While therapeutic appr ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Bactericidal Intravascular Biosensor for Continuous Reading of Lactate in the ICU

    SBC: BIOCREDE INC.            Topic: 300

    DESCRIPTION provided by applicant Our product will monitor intravenous IV blood lactate levels for andgt days of critical ill patients with sepsis organ failure trauma or acute inflammatory response in the ICU and infant patients with congenital heart disease CHD recovering from cardiopulmonary bypass CPB surgery This device will alert doctors or nurses at the ICU when dangerous ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. An innovative metabolic engineering strategy for the discovery of novel macrolide antibiotics

    SBC: ALLUVIUM BIOSCIENCES, INC.            Topic: 300

    DESCRIPTION provided by applicant The rapid emergence of multi drug resistant pathogenic microorganisms represents a major threat to public health placing an ever increasing demand for the discovery of new antibacterial agents Macrolide antibiotics such as the membered macrolide erythromycin and second generation analogs clarithromycin and azithromycin are among the first line therapies ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Routinizing HIV testing for Adolescents

    SBC: MEDIA REZ LLC            Topic: NICHD

    DESCRIPTION provided by applicant This study will aim to assess the feasibility and acceptability of using state of the art social media and game technology to increase HIV testing among adolescents and young adults AYA ages Rates of HIV testing among AYA are low resulting in high proportions of AYA who are positive or unaware of their HIV infection Further public health messages wh ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government